Show
Sort by
-
Implication of inherited genetic variants associated with follicular lymphoma susceptibility in the prognosis of patients treated by immunochemotherapy in PRIMA study
-
Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma : long-term results of the PRIMA study
-
A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma : a retrospective training and validation analysis in three international cohorts
-
Long term follow-up of the PRIMA study : half of patients receiving rituximab maintenance remain progression free at 10 years
-
Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial
-
Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial
-
Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR₃A and FCGR₂A polymorphisms
-
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
-
Pattern of infections observed during the maintenance phase in the PRIMA study
-
Impact of induction chemotherapy regimen on response, safety and outcome in the PRIMA study